Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BDTX
SellSinkerBlack Diamond Therapeutics, Inc. · Healthcare · United States · $128M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing precision medicines for cancer patients with genetically defined mutations. The company utilizes its proprietary Mutation-Allostery-Pharmacology (MAP) platform to discover and develop novel allosteric and mutation-specific therapies for historically undruggable cancer targets. Black Diamond is a niche biotechnology firm focused on addressing high unmet medical needs in precision oncology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 70.0M | — | — | 6.3M | — | -91.1% |
| EPS | -3.47 | -2.52 | -1.88 | -1.27 | 0.39 | — | -0.75 | -0.57 | -1.00 | — |
| Shares | 36.2M | 36.4M | 51.6M | 56.6M | 57.1M | +57.7% | 57.3M | — | — | — |
| Debt | 28.5M | 28.1M | 25.3M | 22.2M | 18.8M | -9.9% | 17.0M | — | — | — |
| Equity | 195.9M | 115.7M | 116.7M | 83.3M | 112.2M | -13.0% | — | — | — | — |
| Op CF | -100.1M | -85.1M | -66.7M | -62.3M | 29.6M | — | -32.8M | — | — | — |
| Inv CF | 130.6M | 53.4M | 16.3M | 17.0M | -44.9M | — | — | — | — | — |
| Fin CF | 0.7M | 0.2M | 71.9M | 25.5M | -0.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BDTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc.(you) | $128M | 22 | Sell |
| NRXP | NRx Pharmaceuticals, Inc. | $154M | 23 | Sell |
| AARD | Aardvark Therapeutics, Inc. | $127M | 18 | Strong Sell |
| VTVT | vTv Therapeutics Inc. | $128M | 18 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 16 | Strong Sell |
| ATRA | Atara Biotherapeutics, Inc. | $92M | 23 | Sell |
| OKUR | OnKure Therapeutics, Inc. | $153M | 26 | Sell |
| CDXS | Codexis, Inc. | $174M | 21 | Sell |
| EQ | Equillium, Inc. | $152M | 27 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 23 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%